Professional athletes suffering from familial hypercholesterolaemia rarely tolerate statin treatment because of muscular problems

British Journal of Clinical Pharmacology

Volumn 57, Issue 4, 2004, Pages 525-528

  Sinzinger, H ^a   O'Grady, J ^a,b  

^a Wilhelm Auerswald Atherosclerosis Research Group   (Austria)

^b UNIVERSITY OF VIENNA   (Austria)

Author keywords

Creatine phosphokinase; Familial hypercholesterolaemia; Muscle pains; Oxidation injury; Professional athletes

Indexed keywords

ATORVASTATIN; CERIVASTATIN; CREATINE KINASE; FLUINDOSTATIN; MEVINOLIN; PRAVASTATIN; SIMVASTATIN; STATINE DERIVATIVE;

ADOLESCENT; ADULT; ARTICLE; ATHLETE; CLINICAL ARTICLE; DRUG TOLERABILITY; EXERCISE; FAMILIAL HYPERCHOLESTEROLEMIA; FEMALE; HUMAN; MALE; MEDICAL DECISION MAKING; MUSCLE CRAMP; MUSCLE DISEASE; MUSCLE WEAKNESS; MYALGIA; OXIDATIVE STRESS; PRESCRIPTION; PRIORITY JOURNAL; RISK FACTOR; SPORT; TRAINING;

ADOLESCENT; ADULT; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPOPROTEINEMIA TYPE II; MALE; MUSCULAR DISEASES; SPORTS;

EID: 1942519775     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2003.02044.x     Document Type: Article

References (14)

1. Gotto AM, Grundy SM. Lowering LDL-cholesterol: questions from recent analysis of clinical trials. Data from the Interdisciplinary Council of Reducing the Risk for Coronary Heart Disease. Circulation 1999; 99: E1-E7.
2. Phillips PS, Haas RH, Bannykh S, Hathaway S, Gray NL, Kimura BJ, England JDF. Statin-associated myopathy with normal creatine kinase levels. Ann Int Med 2002; 137: 581-5.
3. Heart Protection Study Collaborative Group. MRC/BHF Heart protection study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomized placebo-controlled trial. Lancet 2002; 360: 7-22.
4. Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-9.
5. Witztum JL. Drugs used in the treatment of hyperlipoproteinemia. In Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th edn, eds Harrison JG, et al. New York, McGraw-Hill, 1996.
6. Sinzinger H, Schmid P, O'Grady J. Two different types of exercise-induced muscle pain without myopathy and CK-elevation during HMG-Co-enzyme-A-reductase inhibitor treatment. Atherosclerosis 1999; 143: 459-60.
7. Ucar M, Mjörndal T, Dahlqvist R. HMG-CoA reductase inhibitors and myotoxicity. Drug Safety 2000; 29: 441-57.
8. Omar MA, Wilson JP, Cox TS. Rhabdomyolysis and HMG-CoA reductase inhibitors. Am Pharmacol Ther 2002; 35: 1096-107.
9. Sinzinger H, Kritz H, Schwarz B. Austrian Cholesterol Consensus Conference. Richtlinien des Cholesterin-Konsens 1995. Wr Klin Wschr 1995; 107: 537-9.
10. Thompson PD, Zmuda JM, Domalik LJ, Zimet RJ, Staggers J, Guyton JR. Lovastatin increases exercise-induced skeletal muscle injury. Metabolism 1997; 46: 1206-10.
11. 2α is frequently increased in patients with muscle pain and/or CK-elevation after HMG-Co-enzyme-A-reductase inhibitor therapy. J Clin Pharm Ther 2001; 26: 303-10.
12. Sinzinger H. Does vitamin E beneficially affect muscle pains during HMG-CoA enzyme reductase inhibitors without CK-elevation? Atherosclerosis 2000; 149: 225.
13. 2α in heterozygous hypercholesterolemia. Wr Klin Wschr 1999; 111: 113-8.
14. Sinzinger H, Chehne F, Lupattelli G. Oxidation injury in patients receiving HMG-CoA reductase inhibitors. Drug Safety 2002; 25: 877-83.